康柏西普联合玻璃体切割术对糖尿病性黄斑水肿患者房水VEGF、SDF-1的影响

doi:10.12092/j.issn.1009-2501.2019.02.016

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (2): 218-222.doi: 10.12092/j.issn.1009-2501.2019.02.016

康柏西普联合玻璃体切割术对糖尿病性黄斑水肿患者房水VEGF、SDF-1的影响

张皇¹，全婵娟¹，杨新怀¹，黄淑兰¹，高松哲¹，王肖¹，陈荣²，陈岚²

¹南方医科大学附属小榄医院眼科，中山 528415，广东; ² 湖北省应城市人民医院眼科，应城 432400，湖北

收稿日期:2018-07-27 修回日期:2018-10-29 出版日期:2019-02-26 发布日期:2019-03-04
作者简介:张皇，男，硕士，主治医师，研究方向：角膜病，白内障，眼底外科。 Tel: 15171285120 E-mail: zhanghuangzh12@163.com
基金资助:
中山市科技局医疗卫生重大专项（2015B1011）

Effects of conbercept combined with vitrectomy on the aqueous humor VEGF and SDF-1 in patients with diabetic macular edema

ZHANG Huang¹, QUAN Chanjuan¹, YANG Xinhuai¹, HUANG Shulan¹, GAO Songzhe¹, WANG Xiao¹, CHEN Rong², CHEN Lan²

¹ Department of Ophtalmology,Xiaolan Hospital Affiliated to Zhong Shan Medical University, Zhongshan 528415, Guangdong, China; ² Department of Ophtalmology, Yingcheng People's Hospital, Yingcheng 432400, Hubei, China

Received:2018-07-27 Revised:2018-10-29 Online:2019-02-26 Published:2019-03-04

摘要/Abstract

摘要：

目的: 探讨康柏西普联合玻璃体切割术（VT）对糖尿病性黄斑水肿（DME）患者房水血管内皮生长因子（VEGF）、人基质细胞衍生因子1（SDF-1）的影响。方法: 选取2015年3月至2018年3月南方医科大学附属小榄医院眼科收治的DME患者100例（100眼），依据随机数字表法分为VT组和西普组，每组50例，VT组给予VT治疗，西普组在此基础上给予康柏西普玻璃体腔注射治疗，比较两组房水VEGF、SDF-1及并发症、黄斑中心视网膜厚度（CMT）、最佳纠正视力（BCVA）。结果: VT组并发症发生率明显低于西普组，差异有统计学意义（P<0.05）；VT组和西普组术后房水VEGF、SDF-1明显低于术前，且VT组明显低于西普组，差异有统计学意义（P<0.05）；VT组和西普组术后1 d、1个月、3个月CMT、BCVA明显低于术前，且VT组明显低于西普组，差异有统计学意义（P<0.05）。结论: 康柏西普联合VT可有效改善DME患者房水VEGF、SDF-1，有利于减少并发症，且可有效改善患者BCVA、CMT，值得临床作进一步推广。

关键词: 康柏西普, 玻璃体切割术, 糖尿病性黄斑水肿, 血管内皮生长因子, 人基质细胞衍生因子1

Abstract:

AIM: To discuss the effect of conbercept combined with vitrectomy (VT) on the aqueous humor vascular endothelial growth factor (VEGF) and human stromal cell derived factor 1 (SDF-1) in patients with diabetic macular edema (DME). METHODS: A total of 100 patients with DME were selected from March 2015 to March 2018 in our Hospital according to the random digital table method, they were divided into VT group and conbercept group, 50 cases in each group.VT group was given VT treatment while conbercept group was given extra intravitre injection therapy of conbercept. The aqueous humor VEGF, SDF-1 and complications, macular central retinal thickness (CMT), best corrected visual acuity (BCVA) were compared between the two groups. RESULTS: The postoperative aqueous humor VEGF and SDF-1 in the VT group and the conbercept group were significantly lower than those in the preoperative, the postoperative aqueous humor VEGF and SDF-1 in the VT group were significantly lower than those in the conbercept group, the difference was statistically significant (P<0.05). The complication rate in the VT group were significantly lower than those in the conbercept group, the difference was statistically significant (P<0.05). The 1 d, 1 month, 3 months postoperative BCVA and CMT in the VT group and the conbercept group were significantly lower than those in the preoperative, the 1 d, 1 month, 3 months postoperative BCVA and CMT in the VT group were significantly lower than those in the conbercept group, the difference was statistically significant (P<0.05). CONCLUSION: Conbercept combined with VT can effectively improve the aqueous humor VEGF and SDF-1 in patients with DME, which is beneficial to reduce the complications, and it can effectively improve BCVA and CMT in patients, it's worth for further clinical promotion.

Key words: conbercept, vitrectomy, diabetic macular edema, vascular endothelial growth factor, human stromal cell derived factor 1

中图分类号:

R774.5

张皇，全婵娟，杨新怀，黄淑兰，高松哲，王肖，陈荣，陈岚. 康柏西普联合玻璃体切割术对糖尿病性黄斑水肿患者房水VEGF、SDF-1的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 218-222.

ZHANG Huang, QUAN Chanjuan, YANG Xinhuai, HUANG Shulan, GAO Songzhe, WANG Xiao, CHEN Rong, CHEN Lan. Effects of conbercept combined with vitrectomy on the aqueous humor VEGF and SDF-1 in patients with diabetic macular edema[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 218-222.

参考文献

［1］Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal Aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies［J］. Ophthalmol, 2015,122(10): 2044-2052.
［2］Korobelnik JF,Schmidt Do DV,Erf ur th U,et al.Intrav itreal aflibereept for diabetic macular edema［J］.Ophthalmol,2014,121(11):2247-2254.
［3］牛红霞,吉昂.玻璃体腔注射康柏西普联合视网膜光凝治疗糖尿病性黄斑水肿的疗效观察［J］.解放军医学杂志,2018,43(3):268-270.
［4］高静,刘晓,王敏哲,等.VEGF、SDF-1在糖尿病视网膜血管病变发生、发展中的作用及机制［J］.新疆医科大学学报,2016,39(10):1286-1290.
［5］李凤鸣.中华眼科学［M］.第2版.北京:人民卫生出版社,2005:2165-2171.
［6］温积权,曹永葆,汪怿,等.羟苯磺酸钙联合血栓通对糖尿病视网膜病变致患者视野缺损的临床疗效［J］.中国临床药理学杂志,2016,32(1):12-14.
［7］Tripathy K, Sharma YR, Singh HI, et al.Scleral abscess fol-lowing posterior subtenon triamcinolone acetonide injection fordiabetic macular edema［J］. Saudi J Ophthalmol, 2016,30(2):130-132.
［8］于文洲,杨颖.中药联合玻璃体切割术治疗难治性黄斑水肿的疗效分析［J］.中医临床研究,2017,9(9):51-53.
［9］Shimura M,Yasuda K,Minezaki T,et al.Reduction in the fre-quency of intravitreal bevacizumab administrations achieved byposterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema［J］.Jpn J Ophthalmol,2016,60(5):401-407.
［10］戴琰琰,史春生,王勇,等.观察康柏西普联合激光光凝治疗糖尿病性黄斑水肿临床疗效［J］.实用防盲技术,2018,13(1):3-6.
［11］Moon J,Kim M, Sagong M.Combination therapy of intravit-real bevacizumab with single simultaneous posterior subtenontriamcinolone acetonide for macular edema due to branch retinal vein occlusion［J］. Eye (Lond) ,2016,30(8) : 1084-1090.
［12］王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性［J］.眼科新进展,2016,36(5):471-473.
［13］Xu Y, Rong A, Xu W, et al.Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study［J］.BMC Ophthalmol, 2017,17(1):158.
［14］王智勇,刘丽萍,高永峰.糖尿病视网膜病变患者血清Gas6、SDF-1α和SDF-1β变化及意义［J］.国际眼科杂志,2017,17(5):861-864.
［15］Cavalla F, Osorio C, Paredes R, et al. Matrix metalloproteinases regulate extracellular levels of SDF-1/CXCL12, IL-6 and VEGF in hydrogen peroxide- stimulated human periodontal ligament fibroblasts［J］. Cytokine 2015,73 ( 1 ) : 114-121.
［16］蒋莉,李劲,聂爱芹.玻璃体腔注射康柏西普治疗糖尿病黄斑水肿的疗效观察［J］.国际眼科杂志,2017,17(6):1105-1107.
［17］林再雄,李科.玻璃体切割术联合曲安奈德治疗糖尿病性黄斑水肿的黄斑区变化［J］.实用药物与临床,2017,20(3):300-303.
［18］Miller CG, Budoff G,Jeng-Miller KW, et al.Retina specialists treating diabetic macular edema recommend different approaches for patients than they would choose for themselves［J］. Ophthalmic Surg Lasers Imaging Retina, 2016,47(6):544-554.

[1]	卢锐斌, 赵辉, 谢秋玲, 胡露, 郭朝万, 裴运林, 熊盛. 抗FGF-2纳米抗体抑制碱烧伤诱导大鼠角膜血管新生[J]. 中国临床药理学与治疗学, 2021, 26(6): 609-615.
[2]	杨世涛, 祝一虹, 唐文新. 阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 937-942.
[3]	景钦东，刘海鹏，王斌儒，陈康，陈晓. 甲磺酸阿帕替尼治疗进展期胃癌的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(10): 1194-1200.
[4]	曹林忠，汪小敏，张虎林，郭成龙，苏亮磊，刘新宇. 生骨再造丸对兔激素性股骨头坏死VEGF及FLT-1表达的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 874-880.
[5]	李敏江，陈栋，陈文斌. β-肾上腺素能受体阻滞剂和COX-2抑制剂在结直肠癌肝转移中的作用研究[J]. 中国临床药理学与治疗学, 2018, 23(8): 893-899.
[6]	李晓洁，张胜威，王华胜，王东，梅家转，邓业巍. VEGF-A基因多态性对接受氟尿嘧啶为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 900-904.
[7]	罗勇，李崎，华特波. 新辅助化疗联合乳腺癌改良根治术对乳腺癌患者免疫功能、基质金属蛋白酶及血管内皮生长因子的影响[J]. 中国临床药理学与治疗学, 2018, 23(1): 104-109.
[8]	杨红，林杉，杨宏，谢晓薇，王新. 艾拉莫德对类风湿关节炎患者血管内皮生长因子及色素上皮衍生因子表达的影响[J]. 中国临床药理学与治疗学, 2017, 22(1): 68-71.
[9]	陶绍能，王莹莹，戴云海，程光华，吕坤. 体外沉默血管内皮生长因子对D-(-)-MTX/A549耐药细胞株迁移侵袭能力的影响[J]. 中国临床药理学与治疗学, 2016, 21(7): 745-748.
[10]	徐涛，金法，李宁，叶志鹏，吴可人，李志杰. 分化相关基因-1在血管损伤后新生内膜形成中的表达及临床意义[J]. 中国临床药理学与治疗学, 2016, 21(10): 1108-1113.
[11]	陈淑慧, 阳帆帆, 何君, 周鹏, 王桂华. 胃癌靶向治疗研究最新进展[J]. 中国临床药理学与治疗学, 2015, 20(8): 950-955.
[12]	林国芳. 姜黄素对大鼠局灶性脑缺血再灌注血管内皮生长因子和水通道蛋白4的影响[J]. 中国临床药理学与治疗学, 2015, 20(6): 621-624.
[13]	徐晓芳, 张蕾蕾, 贾仁兵, 周一雄, 宋欣, 范先群. 睑板腺癌中MMP-2的表达及其临床意义[J]. 中国临床药理学与治疗学, 2015, 20(5): 557-561.
[14]	姜爱英, 于仁志, 吕玉凤, 罗海龙. 血管内皮生长因子受体抑制剂SU5614对甲苯二异氰酸酯诱导哮喘模型小鼠治疗作用的研究[J]. 中国临床药理学与治疗学, 2015, 20(3): 269-273.
[15]	罗慧英, 杨林, 王晓鹏, 苏河, 刘英, 马云涛, 吴自燕. siRNA沉默胃癌SGC-7901细胞COX-2基因对VEGF-C表达与细胞迁移的影响[J]. 中国临床药理学与治疗学, 2014, 19(9): 961-966.

康柏西普联合玻璃体切割术对糖尿病性黄斑水肿患者房水VEGF、SDF-1的影响

Effects of conbercept combined with vitrectomy on the aqueous humor VEGF and SDF-1 in patients with diabetic macular edema

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价